Mutation Linked to Congenital Urinary Tract Defects
News Jul 18, 2013
Researchers at Columbia University Medical Center (CUMC) and collaborators have identified a genetic mutation that causes congenital malformations of the kidney and urinary tract, a common form of birth defect and the most common cause of kidney failure in children. It is the first time that a specific genetic mutation has been linked to a non-syndromic form of urinary tract malformation. The findings were published in the July 17 online issue of the New England Journal of Medicine.
The research team, led by Ali Gharavi, MD, associate professor of medicine in the Division of Nephrology and a nephrologist at NewYork-Presbyterian Hospital/Columbia University Medical Center, studied a Sardinian family with congenital malformations of the kidney and urinary tract. Several family members had experienced kidney failure at a young age. Using the recently developed tool of exome gene sequencing (sequencing of only the coding parts of the genome), the researchers identified a mutation in a gene called dual serine/threonine and tyrosine protein kinase (DSTYK) in all of the affected family members.
The researchers then screened 311 unrelated individuals with urinary tract defects from centers throughout Europe and found seven other patients with DSTYK mutations. “These findings indicate that DSTYK mutations account for 2.2 percent of urinary tract defects in humans, which is very significant as a single-gene cause of this disease,” says Dr. Simone Sanna-Cherchi, the first author of the study.
Some cases of congenital urinary tract defects present with kidney failure at birth, while others are not evident until complications arise, sometimes not until years later. By defining a new form of disease, these findings will allow clinicians to make a precise molecular diagnosis and identify mutation carriers who may be at risk for complications.
“Exome gene sequencing is now the method of choice for diagnosis of congenital disorders of unknown cause,” says Dr. Gharavi. “It is what enabled us to detect the mutation that was shared by all affected individuals in the Sardinian family.”
Drs. Sanna-Cherchi, Gharavi, and colleagues now plan to use the exome genome sequencing approach to study other patients and define additional forms of congenital urinary tract defects. “By defining new disease categories, we can study each genetic subtype in detail and determine why there is so much variability in the clinical course and complications of these disorders. We will be better able to advise patients on the risk of complications in family members and future offspring,” says Dr. Sanna-Cherchi.
The paper, titled “Mutations in DSTYK and Dominant Urinary Tract Malformations,” is the result of an international collaboration of Columbia University Medical Center and 32 other institutions, including the Giannina Gaslini Institute, Genoa, Italy; the Hospital of Montichiari, Montichiari, Italy; the University of Parma, Parma, Italy; the University of Foggia, Foggia, Italy; the University of Split, Split, Croatia; Yale University School of Medicine, New Haven, Conn.; and Harvard Medical School, Boston, Mass.
This research was supported by the American Heart Association Scientist Development Grant 0930151N, the American Heart Association Grant in Aid 13GRNT14680075, the American Society of Nephrology Carl W. Gottschalk Research Scholar Grant, NIDDK grant K23-DK090207, the Fondazione Malattie Renali nel Bambino (Italy), the American Society of Nephrology, the Doris Duke Charitable Foundation, and the Polish Ministry of Health.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018